Gain Therapeutics to Present at 38th Annual ROTH Conference, CEO Gene Mack to Participate in Fireside Chat and One-on-One Meetings.

Gain Therapeutics will present at the 38th Annual ROTH Conference. Gene Mack, President and CEO, will participate in a fireside chat and one-on-one meetings. Gain is a clinical-stage biotechnology company leading the discovery and development of next-generation allosteric small molecule therapies. Its lead drug candidate, GT-02287, is being evaluated for the treatment of Parkinson's disease.